The Precautionary Patch: Deconstructing the Contamination of Teva-Pregabalin
AI-generated image · Bay Street Wire
Teva Canada's recall of nerve pain medication contaminated with the psychiatric drug sertraline raises critical questions about the efficacy of 'routine testing' in preventing systemic manufacturing failures.
As CBC News first reported, Teva Canada has issued a recall for two lots of its Teva-Pregabalin 150 mg capsules (lot 100070495 and lot 100068913) after "routine testing" identified possible contamination with sertraline, a drug used to treat depression, obsessive-compulsive disorder, and panic disorders.
While Teva Canada describes the recall as a "precautionary measure," the timeline is troubling. The affected products first entered the Canadian market in September 2025, meaning the "routine testing" caught the error nearly a year after distribution began.
The stakes are potentially fatal. Health Canada warned that patients with hypersensitivity or allergies to sertraline could suffer serious allergic reactions, noting that even low exposure could trigger a fatal anaphylactic reaction. In high-stakes pharmaceutical manufacturing, the migration of a psychiatric drug into a nerve pain medication suggests a systemic lapse in quality control that goes beyond a simple "precaution."